The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 9 of the 16 sources its claims cite were checked for support.
Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation
Open accessAbstract
BACKGROUND: Although the mechanism of neuron loss in Alzheimer's disease (AD) is enigmatic, it is associated with cerebral accumulation of Aβ42. The 5XFAD mouse model of amyloid deposition expresses five familial AD (FAD) mutations that are additive in driving Aβ42 overproduction. 5XFAD mice exhibit intraneuronal Aβ42 accumulation at 1.5 months, amyloid deposition at 2 months, and memory deficits by 4 months of age. RESULTS: Here, we demonstrate by unbiased stereology that statistically significant neuron loss occurs by 9 months of age in 5XFAD mice. We validated two Aβ42-selective antibodies by immunostaining 5XFAD; BACE1-/- bigenic brain sections and then used these antibodies to show that intraneuronal Aβ42 and amyloid deposition develop in the same regions where neuron loss is observed in 5XFAD brain. In 5XFAD neuronal soma, intraneuronal Aβ42 accumulates in puncta that co-label for Transferrin receptor and LAMP-1, indicating endosomal and lysosomal localization, respectively. In addition, in young 5XFAD brains, we observed activated Caspase-3 in the soma and proximal dendrites of intraneuronal Aβ42-labeled neurons. In older 5XFAD brains, we found activated Caspase-3-positive punctate accumulations that co-localize with the neuronal marker class III β-tubulin, suggesting neuron loss by apoptosis. CONCLUSIONS: Together, our results indicate a temporal sequence of intraneuronal Aβ42 accumulation, Caspase-3 activation, and neuron loss that implies a potential apoptotic mechanism of neuron death in the 5XFAD mouse.
Overview
CoChat Summary
TL;DR
This study finds that in 5XFAD mice, intraneuronal Aβ42 appears before plaques and is followed by Caspase-3 activation and later neuron loss. The authors argue this supports a correlative apoptotic pathway for neuron death in this AD model.
Key findings
- Unbiased stereology showed significant neuron loss in 5XFAD mice by 9 months of age; the authors estimate a ~25% loss of Layer 5 pyramidal neurons by 12 months.
- Intraneuronal Aβ42 was detected as early as 1.5 months, before plaque appearance at about 2 months, and persisted as plaques increased with age.
- Activated Caspase-3 was present in 5XFAD neurons by 1.5 months and became visible as punctate accumulations by 4 months; by 9 months, activated Caspase-3-positive puncta were found in the same regions as Aβ42 and neuron loss.
- Aβ42 puncta partially co-localized with Transferrin receptor and LAMP1, suggesting localization to the endosomal-lysosomal system.
Methods
- Used the 5XFAD transgenic mouse model and age-matched non-transgenic littermates; also included 5XFAD; BACE1−/− mice as negative controls for Aβ generation.
- Measured neuron number by design-based unbiased stereology on cresyl-violet-stained parasagittal brain sections from female mice at 4, 6, 9, and 12 months.
- Assessed Aβ42 and apoptosis-related markers by immunohistochemistry and confocal immunofluorescence microscopy, including co-staining with Aβ42, Cleaved Caspase-3, NeuN, class III β-tubulin, Transferrin receptor, and LAMP1.
Limitations
- The authors explicitly note that the findings are correlative, so they do not prove that intraneuronal Aβ42 causes Caspase-3 activation or neuron loss.
- They caution that interpretation requires care because the model is an “aggressive amyloid mouse model that overexpresses multiple FAD mutations.”
- Evident from the text: Caspase-3 was not detected in whole-brain homogenates, suggesting region-specific signal may be missed by bulk analysis rather than excluded.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Intraneuronal Aβ42 is partially localized within both endosomes and lysosomes in 5XFAD neurons. Parasagittal brain sections of 5XFAD (A, B, E-K) and 5XFAD; BACE1−/− (C, D) brains were co-stained with anti-Aβ42-selective antibody (A-K) and anti-APP (6E10: B, D; Karen [29]: E) or anti-Transferrin receptor (TfR) (F-H) or anti-LAMP1 (I-K) antibody, and DAPI for nuclei (A-K), and imaged by confocal microscopy. All mice were 4 months old, except mice used for LAMP1 immunostaining were 2 months (I-K). Label colors indicate fluorescence color. Note that APP staining appears widely distributed in the soma and cell surface (B, D, E), while Aβ42 labeling is confined to intraneuronal puncta in 5XFAD mice (A, B, E, F, I). Asterisk in E identifies Aβ42-positive plaque (red) above large pyramidal neuron that exhibits intraneuronal Aβ42 puncta (arrow). lntraneuronal Aβ42 signal is absent in 5XFAD; BACE1−/− neurons (C, D), again demonstrating the Aβ42-selectivity of the antibody. In 5XFAD neurons, intraneuronal Aβ42 co-localizes with Transferrin receptor in early endosomes (F-H) and with LAMP1 in late endosomes and early lysosomes (I-K), at least in part. Scale bar in D = 12μm (A, C); = 20 μm (B, D). Scale bar in K = 12 μm (E); = 20 μm (F-K).](https://figures.cochat.ai/paper-figures/c6d789fe66034ed5991fabe245d83d1b/neuron-loss-in-the-5xfad-mouse-model-of-alzheimers-disease-correlates-with-figure-4.jpg)



Verification
Claims the paper makes
2 Valid · 3 Not valid · 2 Not checked · 28 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“verified that plaque deposition requires BACE1 activity, as previously shown [17-20].”
§ Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation > Results > 5XFAD mice exhibit intraneuronal Aβ42 accumulation that precedes amyloid plaque formation We anticipated that the 5XFAD neuron loss in cortical Layer 5 and subiculum would correspond to an elevated amyloid plaque load in these areas, as we previously observed [10]. To investigate this further, we performed immunohistochemistry using a rabbit monoclonal antibody that selectively recognizes the carboxy (C)-terminal neo-epitope of Aβ42 generated after γ-secretase cleavage; this antibody has minimal cross-reactivity with full-length APP and APP C-terminal fragments (CTFs; Figure 3 and 4). As expected, parasagittal 5XFAD brain sections incubated with the Aβ42 selective antibody displayed a progressive increase in amyloid burden with age (Figure 3A-D). At 4 months, 5XFAD mice exhibited moderate Aβ42 plaque deposition that was more dense in cortical Layer 5 and subiculum (Figure 3A). As 5XFAD mice aged through 6, 9, and 12 months, the number of Aβ42 plaques increased, and deposits began to accumulate in brain regions adjacent to Layer 5 and subiculum, such as CA1/2, CA3, dentate gyrus, Layers 4 and 6 of the cortex, and midbrain (Figure 3B-D). As expected, non-transgenic littermate control mice exhibited no Aβ42–positive deposits at any age (12 months, Figure 3F). As an additional negative control, we immunostained sections from a 9 month-old 5XFAD; BACE1−/− mouse and observed no Aβ42 labeling (Figure 3E). Importantly, the lack of Aβ42 signal in 5XFAD; BACE1−/− brain sections validated the selectivity of our anti-Aβ42 antibody, confirming that the antibody did not cross-react with full length APP or APP C-terminal fragments, and verified that plaque deposition requires BACE1 activity, as previously shown [17-20]. Together, these observations demonstrate that the regions with the greatest age-related Aβ42 deposition are also the same regions that exhibit neuron loss in 5XFAD brain.
What the sources say
- Not checked — no full text of the sourcecites [17] source
- Could not verifycites [18] sourceExperimental — accuracy not yet measured
The Discussion (Figure 4; page unavailable) reports reduced plaque load after 9D5 antibody treatment, but does not address whether plaque deposition requires BACE1 activity. Searches for BACE1 and beta-secretase activity found no passage in our copy that establishes that requirement. (LLM, conf=0.76)
- Could not verifycites [19] sourceExperimental — accuracy not yet measured
The plaque-deposition results (Figure 2, p. 41783) compare APOE genotypes, not BACE1 activity. Searches for “BACE1” and “beta-secretase activity” found no passage in our copy establishing that plaque deposition requires it. (LLM, conf=0.73)
- Could not verifycites [20] sourceExperimental — accuracy not yet measured
The Methods (Cell culture) and Results (Biochemical characterization) mention BACE1 only in the context of cells used to test an antibody. The Background discusses plaque deposition, but our copy does not say that deposition requires BACE1 activity (searched: “BACE1 activity plaque deposition” and “BACE1”). (LLM, conf=0.75)
boostedstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These results, among others, strongly suggest that Aβ42 plays a central early role in the pathophysiology of AD that ultimately leads to the neuron loss and dementia observed in the disorder.”
§ Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation > Background
What the sources say
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports early Aβ accumulation in AD-vulnerable neurons, predominantly Aβ42/43. The Discussion (page unavailable) links intraneuronal Aβ to neuronal death and cognitive impairment in transgenic mice, but does not establish that Aβ42 ultimately causes neuron loss and dementia in people with AD; it says the pathogenic mechanism remains unresolved. (LLM, conf=0.80)
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Introduction and the section on intraneuronal Aβ and neurodegeneration (page not supplied) report that Aβ42 accumulates early in 5XFAD mice and suggest its aggregates may contribute to neurodegeneration and neuron loss. The paper does not establish a central causal role for Aβ42 in human AD or show that it ultimately leads to dementia; it explicitly says the causal link to neuronal degeneration is unproven. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, we demonstrate by unbiased stereology that statistically significant neuron loss occurs by 9 months of age in 5XFAD mice.”
- Also stated in: § 5XFAD mice exhibit progressive neuron loss in cortical Layer 5 and subiculum · plain
“Quantitative analysis of large pyramidal neurons in Layer 5 of the cortex revealed a significant decrease in the number of neurons from 5XFAD mice at 9 and 12 months when compared to age matched non-transgenic littermate control mice (Figure 2A).”
- Also stated in: § Discussion · plain
“However, by 9 months, neuron loss is statistically significant in Layer 5 cortex of 5XFAD mice.”
§ Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation > Abstract > Results
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 5XFAD mice exhibit progressive neuron loss in cortical Layer 5 and subiculum · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results suggest a progressive death of neurons in 5XFAD mice that begins to become a major process around the age of 6 months and culminates in a ~25% loss of Layer 5 pyramidal neurons by 12 months of age.”
- Also stated in: § Discussion · plain
“Our unbiased stereological counting of 5XFAD mice revealed a significant decline in large pyramidal neurons of the Layer 5 cortex starting at 9 months of age.”
§ Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation > Results > 5XFAD mice exhibit progressive neuron loss in cortical Layer 5 and subiculum
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 4 and 6 months of age, no neuron loss in 5XFAD brain was apparent.”
- Also stated in: § 5XFAD mice exhibit progressive neuron loss in cortical Layer 5 and subiculum · plain
“Neuron numbers of 5XFAD mice at younger ages and of all non-transgenic mice were not significantly different from each other.”
§ Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation > Results > 5XFAD mice exhibit progressive neuron loss in cortical Layer 5 and subiculum
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 5XFAD mice exhibit progressive neuron loss in cortical Layer 5 and subiculum · plain
19 more claims
Create a free account to see all 35 claims and every source verdict.
- Probably not a substantial claim. 2
- It may state two separate claims as one. 10
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“5XFAD mice accumulate detectable Aβ42 within neurons by six weeks of age, and extracellular deposits of Aβ by eight weeks, leading to ubiquitous plaque formation in the hippocampus and cortex at six months, coinciding with the start of neuronal loss [35,36].”
From Centella Asiatica Improves Memory and Promotes Antioxidative Signaling in 5XFAD Mice (2019) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This modest global volume reduction is consistent with prior reports of late‐stage morphometric and neurodegenerative changes in 5xFAD mice. 75 , 76”
From Diffusion MRI reveals amyloid plaque–associated cellular signatures through spatial transcriptomic integration (2026) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“5XFAD mice at 23 weeks of age have been shown to have cognitive deficits that are prior to significant neuronal or synaptic loss (Eimer & Vassar, 2013; Oakley et al., 2006).”
From Functional and structural connectome properties in the 5XFAD transgenic mouse model of Alzheimer’s disease (2018) · cites this paper as Eimer & Vassar, 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“previous reports have shown that neuron loss in the cortical layer V and subiculum, but not in other brain regions, is consistently associated with intraneuronal Aβ42 accumulation, Aβ plaque burden, as well as spatial memory deficits and working memory impairment in 5xFAD mice.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we found reduced integrated density staining of NeuN in our 5XFAD mice compared to WT at 6 and 8 months of age in the hippocampus (Figure S3A in supporting information; 6 months: P = 0.0007; 8 months: P = 0.0121), but not in the cortex (Figure S3B; 6 months: P = 0.7957; 8 months: P = 0.7516).”
From The MR1/MAIT cell axis enhances dystrophic neurite development in Alzheimer's disease (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1523/JNEUROSCI.6637-10.2011”
Cited work 10.1523/jneurosci.6637-10.2011 · retracted 2015-02-25 · notice 10.1523/jneurosci.5236-14.2015 · this paper published 2013
Citations
Cites
1 retracted
Winton, M. J., Lee, E. B., Sun, E., Wong, M. M., Leight, S., Zhang, B., Trojanowski, J. Q., & Lee, V. M. ‐. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6637-10.2011 · Cited by 117
RetractedGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“In the case of the 5XFAD model, the mouse overexpresses APP with K670N/M671L (Swedish mutation [12]), I716V (Florida mutation [13]), and V717I (London mutation [14]), and PS1 with M146L and L286V mutations [15].”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 10×
“Together, our results confirm and extend our previous qualitative work [10] and the quantitative study of Jawhar and colleagues [16] demonstrating neuron loss in the 5XFAD model.”
BackgroundResultInfluentialSelf-citationIntracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“In the case of the 5XFAD model, the mouse overexpresses APP with K670N/M671L (Swedish mutation [12]), I716V (Florida mutation [13]), and V717I (London mutation [14]), and PS1 with M146L and L286V mutations [15].”
BackgroundAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 2×
“Importantly, familial AD mutations (FAD) in the genes for amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) that cause AD implicate Aβ as an initiating factor in AD pathogenesis (reviewed in [5,6]).”
BackgroundThe Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
The Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706 · cited 3×
“studies have indicated the presence of Aβ42 in endosomes and late endosomal multivesicular bodies in other models [30-32] and in cathepsin-D-positive puncta of 5XFAD mice [25].”
ResultJawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., & Wirths, O. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.027 · Cited by 623 · cited 6×
“Together, our results confirm and extend our previous qualitative work [10] and the quantitative study of Jawhar and colleagues [16] demonstrating neuron loss in the 5XFAD model.”
BackgroundResultInfluential
Cited by
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
“We also found that the loss of layer-V neurons, a feature of 5XFAD mice (Eimer and Vassar, 2013; Oakley et al., 2006), was more prominent in Trem2−/−5XFAD mice (Fig.”
Spangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695
“Synaptic and neuronal loss is well docu- mented in the 5xfAD model, and is likely one mechanism contributing to deficits in contextual memory (Jawhar et al., 2012; Buskila et al., 2013; Eimer and Vassar, 2013).”
BackgroundInfluentialLee, J.-H., Yang, D.-S., Goulbourne, C. N., Im, E., Stavrides, P., Pensalfini, A., Chan, H., Bouchet-Marquis, C., Bleiwas, C., Berg, M. J., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01084-8 · Cited by 638
Heckmann, B. L., Teubner, B. J. W., Tummers, B., Boada-Romero, E., Harris, L., Yang, M., Guy, C. S., Zakharenko, S. S., & Green, D. R. (2019) · Cell · doi:10.1016/j.cell.2019.05.056 · Cited by 503
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript month old 5xFAD Rubicon−/− mice (Eimer and Vassar, 2013).”
Practical considerations for choosing a mouse model of Alzheimer’s disease
Jankowsky, J. L., & Zheng, H. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0231-7 · Cited by 449
“Neuron loss has been qualitatively described in the subiculum by 9 months of age; in the neocortex, non-biased stereological estimates suggest that 5XFAD mice lose 25–40% of layer 5 pyramidal neurons between 9 and 12 months of age [48, 49].”
Background
Metadata
- Authors
- Eimer, W. A., & Vassar, R.
- Affiliations
- Northwestern University (US)
- Corresponding author
- Vassar, Robert
- Venue
- Molecular Neurodegeneration
- Published
- 2013
- Volume
- 8
- Issue
- 1
- Pages
- 2
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC3552866
- OpenAlex
- W2011982570
- Cited by
- 425
- References
- 50
- Citations by year
- 2026: 40 · 2025: 66 · 2024: 43 · 2023: 43 · 2022: 42 · 2021: 42 · 2020: 37 · 2019: 25 · 2018: 20 · 2017: 21 · 2016: 13 · 2015: 17 · 2014: 13 · 2013: 3
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- MetLife Foundation
- Alzheimer's Association
- Northwestern University (CA060553, NCI CCSG P30 CA060553, P30CA060553)
- National Institutes of Health (CCSG P30, CA-060553, AG022560, NCI CCSG P30 CA060553, CCSG P30 CA060553)
- National Institute on Aging (R01AG022560)
- National Cancer Institute (NCI CCSG P30 CA060553, CA 060553, CCSGP30CA060553, P30CA060553)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neuronal loss, 5xFAD mice, amyloid-beta 42, caspase-3 activation, neuronal apoptosis, stereology, transferrin receptor, LAMP1, lysosomal localization, amyloid deposition, familial Alzheimer's disease mutations, BACE1
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Mice, Transgenic, Neurons, Peptide Fragments, Amyloid beta-Peptides, Mice, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation. https://app.cochat.ai/papers/10.1186/1750-1326-8-2
- The paper
- Eimer, W. A., & Vassar, R. (2013). Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-8-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.